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SUMMARY – The aim of this study was to assess the efficacy of high-sensitivity C-reactive pro-
tein (hsCRP), cardiac troponin T (cTnT) and creatine kinase (CK) as long-term predictors of reduced 
systolic function in patients with acute ST-segment elevation myocardial infarction (STEMI) under-
going primary percutaneous coronary intervention (PCI) with complete revascularization. This pro-
spective study evaluated consecutive patients with acute STEMI who had normal left ventricular 
ejection fraction (LVEF ≥50%) at admission with single-vessel disease and underwent complete revas-
cularization. Blood samples were collected from admission to day 7. The primary endpoint was reduc-
tion of LVEF <50% after 12 months. The study included 47 patients, median age 59±10 years, 74.5% 
of them men. Patients who developed systolic dysfunction (LVEF <50%) had significantly higher 
mean values of cTnT after 24 hours (5.11 vs. 2.82 µg/L, p=0.010) and peak values of CK (3375.5 vs. 
1865 U/L, p=0.008). There was no significant relation between hsCRP and development of reduced 
LVEF (p=0.541). In conclusion, cTnT and CK could serve as long-term predictors of reduced left 
ventricular systolic function (<50%) in acute STEMI patients with normal systolic function at admis-
sion, single-vessel coronary disease and complete revascularization during primary PCI.
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Introduction
Primary percutaneous coronary intervention (PCI) 
is a favorable treatment for patients with acute myo-
cardial infarction with ST-segment elevation (STE-
MI) and is in most instances effective in assessing re-
vascularization1,2. Although completely revascularized 
patients as a heterogeneous population had better 
clinical results than non-revascularized patients, revas-
cularization need not necessarily lead to reperfusion3,4. 
Therefore, patients should be stratified on the basis of 
presenting either low or high risk of developing sys-
tolic dysfunction in order to select high-risk patients 
who could then undergo a stricter clinical follow-up. 
Clinical risk scores and angiographic lesion classifica-
tion have already been used to identify high-risk pa-
tients with acute STEMI. Several of them (e.g., CA-
DILLAC or GRACE) have provided important prog-
nostic information and have already been using bio-
markers as a constituent part5,6. Nowadays, several 
cardiac biomarkers have been used to a great extent by 
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clinicians because of their predictive value for clinical 
outcomes following cardiovascular events7-9. Measur-
ing non-cardiac and cardiac biomarkers may prove to 
be very useful for risk prediction and therefore can fa-
cilitate the selection of high-risk patients. Higher lev-
els of B-type natriuretic peptide (BNP), cardiac tropo-
nin T or I (cTnT or cTnI), and high-sensitivity C-re-
active protein (hsCRP) are proportionally related to 
higher ratios of major cardiovascular events after acute 
coronary syndrome7-10. Due to this fact, the mentioned 
biomarkers presenting different parts of complex 
STEMI pathophysiological mechanisms have been 
used for assessing STEMI risk and prognosis. New 
biomarkers are the focus of many studies since they 
can provide additional risk information; however, they 
are not widely available, especially in developing coun-
tries11. Therefore, our aim was to assess the predictive 
value of routinely available biomarkers, separately or 
combined, on the basis of which clinical risk could be 
predicted in a low-risk group of completely revascular-
ized, single-vessel acute STEMI patients. The above 
mentioned biomarkers were used because they are rou-
tinely available and they present different parts of the 
pathophysiological cascade of the coronary disease, i.e. 
cTnT and creatine kinase (CK) as markers of myocar-
dial necrosis and size of infarction affected myocardi-
um, and hsCRP as a marker of acute inflammatory 
phase, produced in response to inflammation stimuli 
that contribute significantly to atherosclerosis, acceler-
ating both atherosclerosis and plaque rupture and con-
sequential thrombotic complications7-10.
The aim of the study was to investigate the ability 
of cTnT, CK and hsCRP in predicting the long-term 
risk of developing systolic dysfunction after 12 months 
in the population hospitalized with acute STEMI 
with previously normal left ventricular ejection frac-
tion (LVEF) and with single-vessel coronary disease 
undergoing complete and successful revascularization. 
It is noteworthy to disclose that this study included 
the same study population as a previously published 
study by the same authors, in which the predictive role 
of proBNP was evaluated9, the usage of which is too 
expensive in everyday clinical work and cannot be used 
routinely, especially in developing countries.
Materials and Methods
This was a prospective, single-centre study including 
acute STEMI patients hospitalized in the Sestre mi-
losrdnice University Hospital Centre, Zagreb, Croatia. 
We prospectively studied patients that underwent pri-
mary PCI within 12 hours of the onset of symptoms, 
had normal LVEF (≥50%) at admission, had only sin-
Fig. 1. Study flowchart.
STEMI = ST-segment elevation myocardial infarction; LVEF = 
left ventricular ejection fraction; PCI = percutaneous coronary in-
tervention
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gle-vessel coronary disease, and underwent complete 
and successful revascularization (thrombolysis in myo-
cardial infarction (TIMI) III flow and myocardial 
blush grade (MBG) III) during primary PCI. More-
over, patients who had cardiogenic shock, symptoms 
lasting for >12 hours, significant double- or triple-
vessel coronary disease including left main coronary 
artery, unsuccessful reperfusion, history of myocardial 
infarction, and moderate or high degree valvular dis-
ease were excluded from the study (Fig. 1).
Patients were admitted through emergency depart-
ment, where they underwent assessment of the onset 
and duration of pain, comorbidities and risk factors, 
and complete physical status. A 12-lead electrocardio-
gram (ECG) was obtained in all patients and those 
who had acute STEMI immediately underwent pri-
mary PCI. Treatment of all patients was in line with 
the existing international guidelines for PCIs12. All 
patients signed informed consent for PCI and partici-
pation in the study before undergoing primary PCI. 
The study protocol complied with the Good Clinical 
Practice and the Declaration of Helsinki, and the 
Hospital Ethics Committee approved the study.
Coronary angiography
Before the procedure started, all patients received 
300 mg of acetylsalicylic acid (ASA) and 600 mg of 
clopidogrel per os, as well as a total of 100 IU/kg of 
unfractionated heparin (3000-5000 IU iv. in bolus af-
ter arterial sheath placement and additional 3000-
5000 IU before PCI). All coronary angiographies were 
performed using the transfemoral approach. During 
coronary angiography, left ventriculogram was per-
formed and LVEF was calculated in each patient with 
2 standard projections: left anterior oblique 60° and 
right anterior oblique 30°. After detecting the infarct-
related artery, stent implantation in culprit lesion was 
performed using standard techniques12. TIMI angio-
graphic scale and MBG score were used to determine 
revascularization of the infarct-related artery13.
After having undergone primary PCI, all patients 
were admitted to the coronary care unit where they 
received routine therapy for acute STEMI according 
to the international guidelines12, and additional medi-
cal therapy was left to the discretion of the attending 
physician depending on the patient’s clinical status. 
Echocardiography was performed using the standard 
protocol 3-5 days after primary PCI and LVEF was 
calculated using Simpson and Teicholz methods14,15. 
Patients were discharged 7-10 days after admission 
and continued to receive therapy according to the in-
ternational guidelines12, as well as additional medical 
therapy depending on the patient’s clinical status.
Biochemistry and blood sampling
Peripheral blood samples for routine laboratory 
tests were collected into plastic tubes (EDTA 1.5 mg/
mL) and obtained on admission, after 12 h, on day 1 
and on day 7. Lipid profile was measured once, 24 
hours after admission. CK levels were monitored until 
normalization using spectrophotometry (Olympus 
680, Beckman Coulter Inc., California, USA) and the 
laboratory set the reference value between 0 and 153 
U/L at 37 °C. The concentration of cTnT was deter-
mined by using electrochemiluminescence assay (Co-
bas e 411, Roche Diagnostics, Sussex, UK) and posi-
tive cTnT on admission was defined as any value high-
er than 0.1 µg/L. The hsCRP value was measured us-
ing an immunoturbidimetric assay (Olympus 680, 
Beckman Coulter Inc., California, USA) and dichoto-
mized at a the cut-off limit of ≥11 mg/L, as assessed in 
previous studies16-18. Moreover, patients were divided 
into quartiles on the basis of their hsCRP and cTnT 
levels, which is a standard model to assess the impact 
of biomarkers in the population.
Follow-up
During the 12-month follow-up, all patients were 
evaluated at 6 and 12 months. Clinical examination, 
laboratory tests including complete blood count, CK, 
hsCRP, cTnT, NT-proBNP and creatinine, as well as 
ECG stress test were carried out during check-up. 
Also, echocardiography was done at 6 and 12 months 
after discharge and without knowing the biomarker 
results.
Endpoints
The primary endpoint was systolic dysfunction de-
fined as reduced LVEF to less than 50% with or with-
out heart failure clinical signs and symptoms, at 12 
months after acute myocardial infarction.
Statistical analysis
Quantitative data were expressed as median values 
and corresponding ranges. Differences in quantitative 
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variables between the groups were tested by Mann-
Whitney U-test (non-parametric test for independent 
samples). Qualitative data were expressed in contin-
gency tables as absolute values and percentages. The 
relation between qualitative variables and patient 
groups was tested by χ2-test with Yates corrections. 
Association between biomarkers and clinical outcome 
(LVEF <50% or ≥50%) was evaluated by use of logistic 
regression. The distribution of particular variables was 
tested using Kolmogorov-Smirnov test and logarith-
mic transformations were used as appropriate. The 
multivariable model of logistic regression was created 
and its receiver operating characteristic (ROC) curve 
was constructed to assess the accuracy of biomarkers 
and multimarker score to predict clinical outcome 
(LVEF <50%). The values of p<0.05 were considered 
statistically significant. STATISTICA software, ver-
sion 6.0 for Windows (Dell Software, StatSoft Inc., 
Tulsa, USA) was used on statistical analysis.
Results
Out of a total of 220 consecutive acute STEMI pa-
tients admitted to the hospital during the one-year 
study period, 58 patients met the inclusion/exclusion 
criteria (Fig. 1). Additionally, six patients refused to 
participate in the study, whereas five patients dropped 
out during the follow-up period (all underwent fol-
low-up at another institution) (Fig. 1). Consequently, 
the study population included 47 patients, and 74.5% 
of them were male, median age 59±10 years and mean 
body mass index (BMI) 28.9±4.3 kg/m2. The duration 
of chest pain at admission was 137.7±94.5 minutes. At 
admission, all 47 patients had normal systolic function 
(LVEF ≥55%) with single-vessel coronary disease and 
underwent primary PCI with stent implantation and 
complete revascularization. During the 12-month fol-
low-up, 21 patients developed echocardiographic signs 
of reduced LVEF <50%. The study patients were di-
Table 1. Demographic, clinical and angiographic characteristics of two study groups: group A (LVEF <50%)  










Age (years) 59 (37-77) 56 (47-74) 0.471
Body mass index (kg/m2) 27.7 (20.2-31.2) 29.6 (23.9-39.8) 0.031
Sex
male 13 (61.9%) 23 (88.5%) 0.058female 8 (38.1%) 3 (11.5%)
Hypertension 11 (52.4%) 17 (65.4%) 0.681
Diabetes mellitus 9 (42.9%) 12 (46.2%) 0.825
Hyperlipoproteinemia 4 (19.0%) 16 (61.5%) 0.012
Smoking 9 (42.9%) 16 (61.5%) 0.413
Positive family history 11 (52.4%) 16 (61.5%) 0.885
Culprit lesion
LAD 11 (52.4%) 6 (23.1%)
0.048ACx 3 (14.3%) 3 (11.5%)
RCA 6 (28.6%) 17 (65.4%)
hsCRP ≥11 mg/L at admission (mg/L) 3 (14.3%) 0 (0.0%) -
hsCRP ≥11 mg/L after 24 h (mg/L) 17 (80.9%) 19 (73.1%) 0.541
Peak levels of CK (U/L) 3375.5 (1254 – 8310) 1865 (325 – 14297) 0.008
cTnT at admission (µg/L) 0.065(0.01–1.35) 0.052 (0.01-0.65) 0.575
cTnT after 24 h (µg/L) 5.11 (1.08-10.12) 2.825 (0.4-11.62) 0.010
LVEF = left ventricular ejection fraction; LAD = left anterior descending coronary artery; ACx = circumflex coronary artery; 
RCA = right coronary artery; hsCRP = high-sensitivity C-reactive protein; CK = creatine kinase; cTnT = cardiac troponin T
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vided into two groups: group A, LVEF <50% and group 
B, LVEF ≥50%.
Baseline demographic, clinical and angiographic 
characteristics of the two study groups are shown in 
Table 1. Group A patients (LVEF <50%) in compari-
son with group B patients had lower BMI (27.7 vs. 
29.6; p=0.031) and consequently lower incidence of 
hyperlipoproteinemia (20% vs. 61.5%; p=0.012). Oth-
er demographic and clinical characteristics did not dif-
fer significantly between the study groups.
Biomarkers and follow-up outcome
The levels of cTnT at admission did not signifi-
cantly differ between the study groups (p=0.575), as 
opposed to the levels of cTnT after 24 hours, which 
were higher in group A (5.11 vs. 2.82 µg/L; p=0.010). 
When we divided patients into quartiles according to 
cTnT values after 24 hours, odds ratio for the primary 
end-point in patients with cTnT after 24 hours in Q4 
was 6.27 (95% CI, 1.35-29.06; p=0.020) as compared 
with Q1-Q3 patients. Also, the peak values of CK 
were significantly higher in group A (3375.5 vs. 1865 
U/L; p=0.008). There was no significant relation be-
tween hsCRP levels at admission or after 24 hours and 
development of heart failure during the 12-month 
follow-up, either when the values were dichotomized 
at a cut-off limit of ≥11 mg/L (17 patients in group A 
vs. 19 patients in group B; p=0.541) or when they were 
split into quartiles (p=0.848). Predictive values for re-
duced LVEF after 12 months are presented in Table 2.
Additionally, considering infarct-related artery, left 
anterior descending (LAD) artery was more common 
in group A (LVEF <50%), whereas right coronary ar-
tery (RCA) was more common in group B (p=0.048) 
(Table 1); when using logistic regression, we found 
that patients with LAD as an infarct-related artery 
were 4 times more likely to develop LVEF <50% (OR 
4.074; 95% CI 1.11-15.01; p=0.035) (Table 2). Fur-
thermore, we created a biomarker score that included 
peak values of CK and levels of cTnT after 24 hours 




95% confidence interval p valueMinimum Maximum
Body mass index 0.780 0.63 0.97 0.028
RCA 0.227 0.06 0.82 0.025
LAD 4.074 1.11 15.01 0.035
CK (log) 3.168 1.16 8.64 0.025
cTnT after 24 h (log) 3.342 1.17 9.52 0.025
cTnT Q4 after 24 h 6.272 1.35 29.07 0.002
RCA = right coronary artery; LAD = left anterior descending coronary artery; CK = creatine kinase; cTnT = 
cardiac troponin T
Fig. 2. Receiver operating characteristic (ROC) curve 
analysis for multimarker score as a predictor of left 
ventricular systolic dysfunction after 12 months.
Receiver operating characteristic (ROC) curve analysis for multi-
marker score, consisting of cardiac troponin T after 24 h, peak levels 
of creatine kinase and left anterior descending coronary artery as an 
infarct-related artery, as a predictor of left ventricular systolic dys-
function after 12 months. Sensitivity 65.0% (95% confidence inter-
val 11.1-87.9%); specificity 84.6% (95% confidence interval 21.2-
94.5%); area under the ROC curve = 0.825.
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and ROC curve analysis did not show prognostic value 
of this score for predicting reduced systolic function 12 
months after STEMI: sensitivity 70.0% (95% CI 
0-100%) and specificity 80.7% (95% CI 0-100%) with 
the area under the ROC curve 0.817. However, when 
we added LAD as an infarct-related artery to this 
score, the predictive value was slightly better with 65% 
sensitivity (95% CI 11.1-87.9%), 84.6% specificity 
(95% CI 21.2-94.5%), and area under the ROC curve 
= 0.825 (Fig. 2).
Discussion
The study represented a prospective, single-centre ex-
perience in a specific group of patients with acute STE-
MI and only one affected coronary artery that under-
went primary PCI within 12 h of the onset of symptoms 
with successful and complete revascularization. This 
group of patients is considered as low-risk and has the 
best long-term prognosis, as well as a low incidence of 
unwanted outcomes. Therefore, they are often not in the 
primary focus of clinicians, which should not be the case 
since among this population with a great potential of 
complete recovery, there are patients which are at a high-
er risk of developing systolic dysfunction.
According to our findings, which are in agreement 
with most previous similar studies19-21, the levels of 
cTnT after 24 hours, both mean values and when di-
vided into quartiles, as well as the peak levels of CK 
were higher in the group of patients that developed 
reduced systolic function with LVEF <50% after one-
year follow-up, taking into account that patients with 
cTnT in Q4 were six times more likely to develop it. 
Regarding hsCRP, for which the results of previous 
studies are ambiguous17,18,20, we found that the values 
≥11 mg/L did not differ between the study groups, ei-
ther at admission or after 24 hours, and that this bio-
marker had no predictive value in this specific group of 
patients with acute STEMI. Considering the above 
mentioned, cTnT and CK could be used as long-term 
predictors of developing reduced systolic function 
(LVEF <50%) in this very homogeneous group of pa-
tients, usually considered as low-risk population. It is 
important because the long-term prognosis differs con-
siderably for this population and consequently risk strat-
ification is very important. There are a number of stud-
ies investigating the same problem and yielding very 
similar results, but they included more heterogeneous 
groups of patients6,11,16,20. Contrary to previous studies 
in which re-hospitalization, acute coronary syndrome, 
major adverse cardiovascular events or death (sepa-
rately or combined) were taken as an endpoint7,11,16-19, 
our study took systolic dysfunction as an endpoint.
In order to obtain better risk prognosis, there is a 
tendency to develop multimarker scores, which are not 
easy to design but which could provide additional in-
formation and be better in stratifying the risk22. More-
over, several studies showed controversial results re-
garding multimarker scores leading to better risk strat-
ification in comparison to clinical scores6,8,22,23, which 
is in correlation with our results. Non-routinely avail-
able biomarkers were also used in the studies, but they 
proved to be inefficient in several studies, whereas in 
others they provided additional information and im-
proved risk stratification24. However, their usage is too 
expensive and they cannot be used routinely, especially 
in developing countries. Therefore, we studied only 
routinely available biomarkers.
In line with other studies25, we found that LAD as an 
infarct-related artery led to a higher incidence of left 
ventricular systolic dysfunction, which means that pa-
tients with complete revascularization after STEMI and 
with single-vessel disease affecting LAD were at a high-
er risk (odds ratio 4 times higher).
The results of this study should be considered in 
the light of certain limitations. This prospective study 
represented a single-centre experience in a small sam-
ple of patients; however, these patients are very spe-
cific, making a rather small group in the population of 
STEMI patients, and are considered as low-risk with 
the low incidence of unwanted outcomes. Moreover, due 
to the small number of patients, statistical analysis could 
not be performed between particular groups and data 
should be cautiously interpreted. Because of these lim-
itations, our findings will have to be validated in larger 
clinical trials.
In conclusion, cTnT and CK could be predictors of 
left ventricular systolic dysfunction (<50%) in acute 
STEMI patients who had normal systolic function at 
admission, single-vessel coronary disease, and were 
successfully and completely revascularized during pri-
mary PCI. Moreover, a multimarker score consisting 
of cTnT after 24 hours, CK and LAD has a predictive 
value and could also be used as a long-term predictor. 
These biomarkers could be used to differentiate pa-
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tients, in this specific low-risk group of STEMI pa-
tients, who are at a higher risk of developing systolic 
dysfunction, and therefore could be clinically followed-
up more often.
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Sažetak
RUTINSKI DOSTUPNI BIOMARKERI KAO PREDIKTORI RAZVOJA SISTOLIČKE DISFUNKCIJE  
TIJEKOM DUGOROČNOG PRAĆENJA BOLESNIKA S POTPUNO REVASKULARIZIRANIM  
AKUTNIM INFARKTOM MIOKARDA SA ST ELEVACIJOM
I. Zeljković, Š. Manola, V. Radeljić, D. Delić Brkljačić, A. Babacanli i N. Pavlović
Cilj istraživanja bio je utvrditi učinkovitost visokoosjetljivog C-reaktivnog proteina (hsCRP), kardijalnog troponina T 
(cTnT) i kreatin kinaze (CK) kao dugoročnih prediktora razvoja sistoličke disfunkcije u bolesnika sa STEMI-infarktom 
kojima je učinjena potpuna revaskularizacija tijekom primarne perkutane koronarne intervencije (PCI). Provedena je pros-
pektivna studija kojom su evaluirani uzastopni bolesnici s akutnim STEMI-infarktom koji su imali urednu sistoličku funk-
ciju kod prijma uz jednožilnu koronarnu bolest i koji su potpuno revaskularizirani tijekom primarne PCI. Uzorci krvi su 
prikupljani od prijma do 7. dana hospitalizacije. Primarni ishod bio je razvoj sistoličke disfunkcije lijevog ventrikla (LVEF 
<50%) nakon godinu dana. U istraživanje je bilo uključeno 47 bolesnika s medijanom dobi 59±10 godina i 74,5% su bili 
muškarci. Bolesnici koji su razvili sistoličku disfunkciju (LVEF <50%) su imali značajno više vrijednosti cTnT nakon 24 sata 
(5,11 prema 2,82 µg/L, p=0,010) i više maksimalne vrijednosti CK (3375,5 prema 1865 U/L, p=0,008). Nije utvrđena pove-
zanost između hsCRP-a i razvoja sistoličke disfunkcije (p=0,541). Zaključak je da cTnT i CK mogu poslužiti kao dugoročni 
prediktori snižene sistoličke funkcije lijevog ventrikla (<50%) u bolesnika s akutnim STEMI-infarktom koji su imali urednu 
sistoličku funkciju kod prijma uz jednožilnu koronarnu bolest i koji su potpuno revaskularizirani tijekom primarne PCI.
Ključne riječi: Infarkt miokarda; C-reaktivni protein; Kreatin kinaza; Troponin T; Perkutana koronarna intervencija; 
 Prognoza
